Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 142 of the 143 references it cites were found in a registry or an index; 63 of the 190 sources its claims cite were checked for support.

Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms

Open access

Abstract

BACKGROUND: The prevalence of autism spectrum disorder (ASD) has surged, with an estimated 1 in 36 eight-year-olds in the United States meeting criteria for ASD in 2020. Autistic individuals face elevated rates of co-occurring medical, psychiatric, and behavioral conditions compared to non-autistic individuals. The rising ASD-patient demand is increasingly outpacing the capacity of ASD-specialty clinics, resulting in urgent need for autism-competent providers in general practice settings. This work aims to empower healthcare providers, especially primary care providers (PCPs), with guidelines for the recognition and safe pharmacologic management of common co-occurring psychiatric and behavioral conditions in ASD. METHODS: Lurie Center for Autism medical providers, who have extensive experience in ASD care, delineated approaches for recognition and pharmacological treatment of sleep disturbances, attention-deficit/hyperactivity disorder (ADHD), anxiety, depression, and irritability tailored to ASD patients. Pharmacological guidelines were iteratively refined until consensus was reached. Treatment differences relative to standard of care (SOC) of non-autistic individuals are noted. Key literature and clinical trial results were reviewed to supplement clinical experience. RESULTS: -adrenergic agonists are more suitable than stimulants for some ASD-ADHD patients, buspirone and mirtazapine are preferred to selective serotonin reuptake inhibitors (SSRIs) for anxiety, and duloxetine, mirtazapine, bupropion, and vortioxetine are recommended ahead of SSRIs for depression. Addressing irritability in ASD requires interdisciplinary evaluation of contributing factors, and guanfacine, risperidone, or aripiprazole may be appropriate, depending on severity. CONCLUSIONS: Recognition and treatment of co-occurring psychiatric and behavioral conditions in autistic patients must account for differences in clinical presentation and medication effectiveness and tolerability. Drawing on evidence-based clinical insights, these guidelines seek to support PCPs in making informed decisions when prescribing medications for ASD patients with co-occurring psychiatric and behavioral conditions, ultimately enhancing access to timely, comprehensive care for all individuals with ASD.

Overview

CoChat Summary

## TL;DR

This paper is an expert-consensus proposal for ASD-specific prescribing guidance for five common co-occurring symptom domains: sleep disturbances, ADHD, anxiety, depression, and irritability. It argues that medication choices, dosing, and monitoring in autism often differ from non-autistic standard of care and are especially relevant for primary care providers.

## Key findings

  • The authors state that in ASD, first-line approaches for sleep disturbance still align with non-autistic care: sleep hygiene and melatonin; they report melatonin had an average overall improvement rate of over 84% across 18 studies and recommend 1–3 mg about 30 min before sleep, titrating up to 10 mg.
  • For ADHD in ASD, they report a 4-week crossover RCT of methylphenidate in 72 children aged 5–14 years where 35/72 (49%) were responders, but 18% discontinued due to adverse events; they also report an 8-week RCT of guanfacine ER in 62 children aged 5–14 years where ABC-Hyperactivity fell 43.6% vs 13.2% on placebo and response was 50% vs 9.4%.
  • For anxiety in ASD, they cite a 10-week RCT of mirtazapine in 30 youth aged 5–17 years: 47% on mirtazapine were “much improved” or “very much improved” vs 20% on placebo, with a non-significant PARS trend (effect size 0.63); they recommend buspirone and mirtazapine ahead of SSRIs.
  • For depression in ASD, the paper reports there are no RCTs of antidepressant treatment specifically for depression in ASD, and recommends duloxetine, mirtazapine, bupropion, and vortioxetine ahead of SSRIs; for irritability, it notes guanfacine may be used first, with risperidone or aripiprazole for more severe cases.

## Methods

  • Expert-consensus guideline development by clinicians and researchers from the Lurie Center for Autism, based on their clinical experience treating ASD across the lifespan.
  • The team iteratively drafted pharmacologic pathways for sleep, ADHD, anxiety, depression, and irritability, then revised them through interviews, feedback, and cross-checking until consensus was reached.
  • They supplemented clinical expertise with a targeted literature search using PubMed and Google Scholar, emphasizing seminal and recent studies and current recommendations.

## Limitations

  • The paper explicitly says the guidance is based on consensus from a single site, with many prescribers sharing similar training or mentoring backgrounds, which limits the breadth of perspectives.
  • The authors state their clinic is highly specialized, so their experience may be biased toward a particular patient population; they also note the manuscript focuses mainly on psychopharmacology and does not cover the full range of behavioral/therapeutic approaches or the needs of people with co-occurring genetic syndromes.
  • Evident from the text: much of the evidence base is limited; the paper repeatedly notes few RCTs, no RCTs for several medications/indications in ASD, and a lack of validated diagnostic and outcome measures for co-occurring conditions in ASD.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s12916-024-03814-0

Cites

142 of 142 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Pharmacological treatment pathway for sleep disturbances in patients with ASD
Fig. 1 Pharmacological treatment pathway for sleep disturbances in patients with ASDCC BY-NC-ND · PubMed Central
Fig. 2 Pharmacological treatment pathway for ADHD in patients with ASD
Fig. 2 Pharmacological treatment pathway for ADHD in patients with ASDCC BY-NC-ND · PubMed Central
Fig. 3 Pharmacological treatment pathway for anxiety in patients with ASD
Fig. 3 Pharmacological treatment pathway for anxiety in patients with ASDCC BY-NC-ND · PubMed Central
Fig. 4 Pharmacological treatment pathway for depression in patients with ASD
Fig. 4 Pharmacological treatment pathway for depression in patients with ASDCC BY-NC-ND · PubMed Central
Fig. 5 Pharmacological treatment pathway for irritability in patients with ASD
Fig. 5 Pharmacological treatment pathway for irritability in patients with ASDCC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

47 Valid · 6 Not valid · 86 Not checked · 38 Own results and interpretations

73 more claims · 15 with their cited sources checked

Create a free account to see all 177 claims and to verify the 16 references still open.

See all claims — free account
  • Probably not a substantial claim. 53
  • It may state two separate claims as one. 67

Create a free account to see these claims.

Citations

Cites

Show all 143 references

Research works printed but not linked: 2

  1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fifth edition, text revision (DSM-5-TR®): Test questions for the diagnostic criteria. Muskin PR, Dickerman AL, Drysdale A, Holderness CC, editors. Arlington, TX: American Psychiatric Association Publishing; 2023. 1120 p.
  2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, 4th Ed. Washington, DC; 1994.

Cited by

See all 51

Metadata

Authors
Manter, M. A., Birtwell, K. B., Bath, J., Friedman, N. D. B., Keary, C. J., Neumeyer, A. M., Palumbo, M. L., Thom, R. P., Stonestreet, E., Brooks, H., Dakin, K., Hooker, J. M., & McDougle, C. J.
Affiliations
  • Massachusetts General Hospital (US)
  • Harvard University (US)
  • Beth Israel Deaconess Medical Center (US)
Corresponding author
McDougle, Christopher J.
Venue
BMC Medicine
Published
2025-01-07
Volume
23
Issue
1
Pages
11-11
ISSN
1741-7015 (ISSN-L)
OpenAlex
W4406116750
Cited by
51
References
143
Citations by year
2026: 34 · 2025: 17
FWCI
8.47
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Medicine (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Psychiatry and Mental health › Child Nutrition and Feeding Issues
Keywords
autism spectrum disorder, pharmacotherapy, primary care, sleep disorders, attention deficit hyperactivity disorder, anxiety, depression, irritability, sympathomimetic drugs, buspirone, mirtazapine, duloxetine, guanfacine, risperidone, aripiprazole, drug tolerability
MeSH terms
Autism Spectrum Disorder, Anxiety, Attention Deficit Disorder with Hyperactivity, Depression, Humans, Sleep Wake Disorders, Comorbidity, Practice Guidelines as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms. https://app.cochat.ai/papers/10.1186/s12916-024-03814-0
The paper
Manter, M. A., Birtwell, K. B., Bath, J., Friedman, N. D. B., Keary, C. J., Neumeyer, A. M., Palumbo, M. L., Thom, R. P., Stonestreet, E., Brooks, H., Dakin, K., Hooker, J. M., & McDougle, C. J. (2025). Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms. BMC Medicine. https://doi.org/10.1186/s12916-024-03814-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.